Texas Permanent School Fund Corp Reduces Holdings in Amedisys, Inc. (NASDAQ:AMED)

Texas Permanent School Fund Corp lowered its position in Amedisys, Inc. (NASDAQ:AMED) by 3.8% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 27,479 shares of the health services provider’s stock after selling 1,081 shares during the period. Texas Permanent School Fund Corp owned 0.08% of Amedisys worth $2,523,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Banque Cantonale Vaudoise purchased a new stake in Amedisys in the 1st quarter valued at $60,000. Innealta Capital LLC acquired a new position in Amedisys in the second quarter valued at approximately $64,000. Covestor Ltd grew its position in Amedisys by 134.2% in the first quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock worth $72,000 after acquiring an additional 447 shares during the period. Signaturefd LLC increased its stake in Amedisys by 88.2% during the second quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock worth $104,000 after acquiring an additional 530 shares during the last quarter. Finally, GAM Holding AG purchased a new stake in Amedisys in the second quarter valued at $275,000. Institutional investors and hedge funds own 94.36% of the company’s stock.

Analyst Upgrades and Downgrades

AMED has been the subject of a number of recent analyst reports. William Blair downgraded Amedisys from an “outperform” rating to a “market perform” rating in a research report on Monday, July 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $101.00 price objective on shares of Amedisys in a research note on Thursday, July 25th. Finally, Deutsche Bank Aktiengesellschaft cut Amedisys from a “buy” rating to a “hold” rating and set a $101.00 target price for the company. in a report on Monday, July 29th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $100.67.

Amedisys Price Performance

Shares of NASDAQ AMED opened at $96.91 on Tuesday. The stock’s 50-day simple moving average is $97.74 and its 200-day simple moving average is $94.73. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.16 and a current ratio of 1.16. The firm has a market capitalization of $3.17 billion, a PE ratio of -151.42, a price-to-earnings-growth ratio of 1.89 and a beta of 0.78. Amedisys, Inc. has a fifty-two week low of $89.55 and a fifty-two week high of $98.95.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, July 24th. The health services provider reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.10. Amedisys had a net margin of 4.02% and a return on equity of 12.39%. The business had revenue of $591.19 million during the quarter, compared to analysts’ expectations of $579.34 million. As a group, equities research analysts forecast that Amedisys, Inc. will post 4.66 EPS for the current fiscal year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.